These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12182760)

  • 1. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.
    Levitt DG
    BMC Clin Pharmacol; 2002 Aug; 2():5. PubMed ID: 12182760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial.
    Levitt DG
    BMC Res Notes; 2009 Aug; 2():158. PubMed ID: 19656378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics.
    Levitt DG
    BMC Clin Pharmacol; 2002 Aug; 2():4. PubMed ID: 12182761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of the interstitial space in humans.
    Levitt DG
    BMC Clin Pharmacol; 2003 Jul; 3():3. PubMed ID: 12890292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.
    Levitt DG
    BMC Clin Pharmacol; 2002 Sep; 2():7. PubMed ID: 12323078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics.
    Levitt DG
    BMC Anesthesiol; 2002 Aug; 2(1):5. PubMed ID: 12182764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption.
    Levitt DG
    BMC Clin Pharmacol; 2003 Mar; 3():1. PubMed ID: 12659643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKQuest: PBPK modeling of highly lipid soluble and extracellular solutes.
    Levitt DG
    ADMET DMPK; 2019; 7(1):60-75. PubMed ID: 35350744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.
    Wang Y; Wang Z; Zuo Z; Tomlinson B; Lee BT; Bolger MB; Chow MS
    AAPS J; 2013 Jul; 15(3):787-96. PubMed ID: 23605805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
    Levitt DG; Schoemaker RC
    BMC Clin Pharmacol; 2006 Jan; 6():1. PubMed ID: 16398929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
    Levitt DG
    BMC Clin Pharmacol; 2004 Feb; 4():2. PubMed ID: 15053829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human physiologically based pharmacokinetic model for propofol.
    Levitt DG; Schnider TW
    BMC Anesthesiol; 2005 Apr; 5(1):4. PubMed ID: 15847680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.
    Sica D; Frishman WH; Manowitz N
    Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of small intestinal permeability during normal human drug absorption.
    Levitt DG
    BMC Pharmacol Toxicol; 2013 Jun; 14():34. PubMed ID: 23800230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
    Kalam MN; Rasool MF; Alqahtani F; Imran I; Rehman AU; Ahmed N
    Drug Des Devel Ther; 2021; 15():1195-1211. PubMed ID: 33762817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects.
    Kiriyama A; Honbo A; Nishimura A; Shibata N; Iga K
    Regul Toxicol Pharmacol; 2016 Apr; 76():21-9. PubMed ID: 26773344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of human adipose blood flow.
    Levitt DG
    BMC Clin Pharmacol; 2007 Jan; 7():1. PubMed ID: 17239252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.